Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Sygnature Discovery Ltd.. (2/15/19). "Press Release: Sygnature Discovery Starts 2019 with Two Senior Appointments – Dr Allan Jordan and Ms Louisa Jordison". Nottingham.

Organisations Organisation Sygnature Discovery Ltd.
  Organisation 2 Cancer Research UK
  Group Cancer Research UK (CRUK) (Group)
Products Product drug discovery services
  Product 2 oncology
Persons Person Jordison, Louisa (Sygnature Discovery 201902– Director of Strategic Planning before Experian + Deloitte + KPMG)
  Person 2 Hirst, Simon (Sygnature Discovery 201112 CEO + Founder)
     


Sygnature Discovery, the leading independent integrated drug discovery and pre-clinical services provider, have made two key appointments. Dr Allan Jordan and Ms Louisa Jordison have joined the organisation as they continue their strong growth trajectory in the drug research market.

Allan comes on-board as Director of Oncology Drug Discovery and in this new role his primary focus will be to augment Sygnature’s existing Oncology drug discovery capabilities and Cellular Biology. Allan joins Sygnature from Cancer Research UK where he worked for the past decade. A very well-known and respected figure in the global Oncology research sector, his appointment plays a key part in Sygnature’s continuous strengthening of their world leading expertise in their key therapeutic areas, which in addition to Oncology are Neuroscience and Immunology.

Louisa joins Sygnature in the newly-created position of Director of Strategic Planning. She will play a key role in the company’s ambitious planning, growth and capital projects activities. Louisa brings a wealth of experience in senior level Corporate Finance from companies including Experian, Deloitte and KPMG.

Sygnature Discovery’s CEO, Dr Simon Hirst commented: "Louisa’s and Allan’s appointments mark a further step in the development of Sygnature as a leading player in the global drug discovery and pre-clinical CRO sector. They demonstrate our commitment to sustainable and secure growth of our company and continuing to broaden and enrich our in-house capabilities and therapeutic area expertise so that we are in an optimal position to serve our growing customer base".


-Ends-


About Sygnature Discovery

Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services company. Private equity-backed since 2017, we operate fully-enabled research facilities in Nottingham and Alderley Park, UK, housing over 200 research scientists (over 80% with PhDs) and have an office presence in Cambridge, Massachusetts, USA. Our experienced drug hunters possess all the professional skills and know-how required to undertake the most demanding of research programmes and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Since 2011, we have delivered 14 drug candidates to our clients which have subsequently entered the clinic (Phases I, II and III). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade.

For further information, visit: www.sygnaturediscovery.com or email: a.lindstrom@sygnaturediscovery.com

   
Record changed: 2019-02-20

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Sygnature Discovery Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top